NASDAQ:ABUS - Arbutus Biopharma Stock Price, Forecast & News

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma Corp (NASDAQ:ABUS) released its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.09. The biopharmaceutical company earned $1.20 million during the quarter. Arbutus Biopharma had a negative return on equity of 298.87% and a negative net margin of 2,416.39%. View Arbutus Biopharma's Earnings History.

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Arbutus Biopharma.

5 equities research analysts have issued 12-month target prices for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Arbutus Biopharma's share price to reach $7.25 in the next year. This suggests a possible upside of 148.3% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.

News headlines about ABUS stock have been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arbutus Biopharma earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Arbutus Biopharma.

Arbutus Biopharma saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 587,600 shares, a decrease of 31.5% from the January 30th total of 858,100 shares. Based on an average daily volume of 582,200 shares, the short-interest ratio is currently 1.0 days. Approximately 1.4% of the shares of the company are short sold. View Arbutus Biopharma's Current Options Chain.

Some companies that are related to Arbutus Biopharma include DiaMedica Therapeutics (DMCAF), Collegium Pharmaceutical (COLL), Aprea Therapeutics (APRE), Phoenix Tree (IMAB), Arcus Biosciences (RCUS), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Frequency Therapeutics (FREQ), Retrophin (RTRX), ImmunoGen (IMGN), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), Akero Therapeutics (AKRO), Provention Bio (PRVB) and Cara Therapeutics (CARA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), Alibaba Group (BABA), Arrowhead Pharmaceuticals (ARWR), Abeona Therapeutics (ABEO), Inovio Pharmaceuticals (INO), NewLink Genetics (NLNK) and GoPro (GPRO).

Arbutus Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (4.74%), Point72 Asset Management L.P. (3.05%), Cowen AND Company LLC (1.49%), Bank of Montreal Can (1.15%), UBS Group AG (0.39%) and Credit Suisse AG (0.23%). View Institutional Ownership Trends for Arbutus Biopharma.

ABUS stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Bank of America Corp DE and Goldman Sachs Group Inc.. View Insider Buying and Selling for Arbutus Biopharma.

ABUS stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Cowen AND Company LLC, Credit Suisse AG, UBS Group AG, Geode Capital Management LLC, Simplex Trading LLC and Oxford Asset Management LLP. View Insider Buying and Selling for Arbutus Biopharma.

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABUS stock can currently be purchased for approximately $2.92.

Arbutus Biopharma has a market capitalization of $181.36 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.View Additional Information About Arbutus Biopharma.

The official website for Arbutus Biopharma is http://www.arbutusbio.com/.

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]